863015-82-1

Basic information

• Product Name: [1,3,4]OXATHIAZINANE 3,3-DIOXIDE
• Synonyms: [1,3,4]OXATHIAZINANE 3,3-DIOXIDE
• CAS NO: 863015-82-1
• Molecular Formula: C3H7NO3S
• Molecular Weight: 137.16
• Mol File: 863015-82-1.mol

Chemical Properties

• Boiling Point: 274.5±50.0 °C(Predicted)
• Appearance: /
• Density: 1.370±0.06 g/cm3(Predicted)
• PKA: 9.77±0.20(Predicted)
• CAS DataBase Reference: [1,3,4]OXATHIAZINANE 3,3-DIOXIDE(CAS DataBase Reference)
• NIST Chemistry Reference: [1,3,4]OXATHIAZINANE 3,3-DIOXIDE(863015-82-1)
• EPA Substance Registry System: [1,3,4]OXATHIAZINANE 3,3-DIOXIDE(863015-82-1)

Safety Data

• Hazardous Substances Data: 863015-82-1(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
[1,3,4]OXATHIAZINANE 3,3-DIOXIDE is used as a key building block for the synthesis of various pharmaceuticals. Its unique structure allows it to be a valuable component in the development of new drugs with potential therapeutic benefits.
Used in Agricultural Products:
In the agricultural sector, [1,3,4]OXATHIAZINANE 3,3-DIOXIDE is utilized as a fundamental component in the creation of different agricultural products, contributing to advancements in crop protection and enhancement.
Used in Anti-inflammatory Applications:
[1,3,4]OXATHIAZINANE 3,3-DIOXIDE is studied for its potential as an anti-inflammatory agent, which could be beneficial in the treatment of various inflammatory conditions and diseases.
Used in Anti-cancer Applications:
[1,3,4]OXATHIAZINANE 3,3-DIOXIDE is also being investigated for its anti-cancer properties, with the potential to contribute to the development of novel cancer therapies and treatments.
Used as a Catalyst in Chemical Reactions:
[1,3,4]OXATHIAZINANE 3,3-DIOXIDE has been explored for its potential use as a catalyst, which could improve the efficiency and selectivity of various chemical reactions in research and industrial processes.

Upstream product

• 109-85-3 2-methoxyethylamine 
• 863015-81-0 4-benzyl-1,3,4-oxathiazinane 3,3-dioxide 

Downstream Products

• 1609356-30-0 tert-butyl 2-chloro-4-(3,3-dioxido-1,3,4-oxathiazinan-4-yl)benzoate 
• 1609356-28-6 tert-butyl 4-(3,3-dioxido-1,3,4-oxathiazinan-4-yl)benzoate 
• 1609356-20-8 methyl 4-(3,3-dioxido-1,3,4-oxathiazinan-4-yl)-2-fluorobenzoate 

Relevant articles and documents

6,7-DIHYDRO-4H-PYRAZOLO[1,5-A]PYRAZINE AND 6,7-DIHYDRO-4H-TRIAZOLO[1,5-A]PYRAZINE COMPOUNDS FOR THE TREATMENT OF INFECTIOUS DISEASES

The present invention relates to compounds of the formula (I), or pharmaceutically acceptable salts, enantiomer or diastereomer thereof, wherein R1 to R4 and Q are as described above. The compounds may be useful for the treatment or prophylaxis of hepatitis B virus infection.

Carbazole-containing sulfonamides and sulfamides: Discovery of cryptochrome modulators as antidiabetic agents

A series of novel carbazole-containing sulfonamides and sulfamides were synthesized. A structure-activity relationship study of these compounds led to the identification of potent cryptochrome modulators. Based on the results of efficacy studies in diet-induced obese (DIO) mice, and the desired pharmacokinetic parameters, compound 41 was selected for further profiling.

CYCLIC SULFONAMIDE CONTAINING DERIVATIVES AS INHIBITORS OF HEDGEHOG SIGNALING PATHWAY

The invention relates generally to the creation and use of cyclic sulfonamide containing derivatives to inhibit the hedgehog signaling pathway and to the use of those compounds for the treatment of hyperproliferative diseases and angiogenesis mediated diseases.

Beta-aminoacid-derivatives as factor Xa inhibitors

The present invention relates to compounds of the formula I, in which R0 ; R1 ; R2 ; R3 ; R4; R5, R6, Q; V, G and M have the meanings indicated in the claims. The compounds of the formula I are valuable pharmacologically active compounds. They exhibit a strong antithrombotic effect and are suitable, for example, for the therapy and prophylaxis of cardiovascular disorders like thromboembolic diseases or restenoses. They are reversible inhibitors of the blood clotting enzymes factor Xa (FXa) and/or factor VIIa (FVIIa), and can in general be applied in conditions in which an undesired activity of factor Xa and/or factor VIIa is present or for the cure or prevention of which an inhibition of factor Xa and/or factor VIIa is intended. The invention furthermore relates to processes for the preparation of compounds of the formula I, their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical preparations comprising them.